DUBLIN–(BUSINESS WIRE)–The “Drug Patent Database Subscription: Pharmaceutical Drugs” newsletter has been added to ResearchAndMarkets.com’s offering.
This subscription was created to answer a simple question: When do drug patents expire? Your needs evolve as the industry keeps changing. Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.
This subscription for the Pharmaceutical Drugs portion of the database offers information on:
- US & International Patents, including active and expired patents in 134 Countries, regulatory protections and exclusivities;
- Information that anticipates drug entries into the generic market, including Loss-of-Exclusivity Dates, Paragraph IV Challenges, Tentative Approvals, Authorized Generics, and more
- Commercial Opportunities, including Single Source Off-Patent Drugs, and the ability to search Patents by Dosage Form/Therapeutic Class
- Information on Drug Sourcing, including API Vendors, Finished Product Suppliers and First Generic Entrants.
Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. The analyst understands and works together with you to help you make better decisions. If you are expanding into new markets, looking inward for growth opportunities, or seeking to improve your current activities and need to find information quickly, this subscription can help.
The analyst provides relevant context and ensures you have the information you need at your fingertips. This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches. The sophisticated algorithms are also tailored to help you extract valuable insights.
With a single click, you can find answers to complex questions such as:
- Which drugs have no patents and no competitors?
- What are all the patents covering any given dosage form (e.g. injectables)?
- What is the earliest generic entry opportunity date for a drug with dozens of patents?
- The analyst focuses on delivering the greatest value and lowest cost by directing attention to high-impact problems, giving you the relevant information you need.
The Pharmaceutical Drugs Plan Database helps drug companies make better decisions through the delivery of cutting-edge business intelligence. The Pharmaceutical Drug plan is focused on the interests of small-molecule drug manufacturers, suppliers, distributors, and payers.
Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events.
Key Topics Covered
- Expired, Pending, and Abandoned Patents
- Active US & International Patents
- Single Source Drugs, Tentative Approvals, Authorized Generics, Paragraph IV Challenges, and more
- Clinical Trials
- API Vendors
Companies Mentioned
- 3M Pharmaceuticals
- Abbott Laboratories
- AbbVie
- Acadia Pharmaceuticals
- Acorda Therapeutics
- Actavis
- Actelion
- Adcock Ingram
- Advanced Chemical Industries
- Advaxis
- ACG Worldwide
- Ajanta Pharma
- Alcon
- Alembic Pharmaceuticals Ltd
- Alexion Pharmaceuticals
- Alkaloid AD Skopje
- Alkermes
- Allergan
- Alliance Boots
- Almirall
- Alphapharm
- Altana Pharma AG
- Amgen
- Anfatis
- Apotex Inc.
- Aspen Pharmacare
- Astellas Pharma
- AstraZeneca
- Aurobindo Pharma
- Avax Technologies
- Avella Specialty Pharmacy
- Axcan Pharma
- Bargn Farmaceutici Phils Co
- Barr Pharmaceuticals
- Bausch & Lomb
- Baxalta
- Baxter International
- Bayer Schering Pharma AG
- Beximco Pharmaceuticals Ltd
- Bial
- Biocon
- Biogen
- Biolex
- BioMarin Pharmaceutical
- Bionovo
- Biotecnol
- Biovail
- Biovitrum
- Bluepharma
- Boehringer-Ingelheim
- Bosnalijek
- Bristol-Myers Squibb
- BTG plc
- Cadila Healthcare
- Canadian Plasma Resources
- Catalent
- The Cathay Drug Co., Inc.
- Celgene
- Cephalon
- Chiesi Farmaceutici S.p.A.
- Chugai Pharmaceutical Co.
- CinnaGen
- Cipla
- Clovis Oncology
- CoCo Therapeutics
- Concordia Healthcare
- Covance
- Crucell
- CSL Limited
- Dabur
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dawakhana Shifaul Amraz
- Debiopharm
- Deurali-Janta Pharmaceuticals
- Diabetology Ltd
- Diffusion Pharmaceuticals
- Dr. Reddy’s Laboratories
- Ego Pharmaceuticals
- Eisai
- Elder Pharmaceuticals
- Eli Lilly and Company
- Emcure Pharmaceuticals
- Emergent BioSolutions
- Endo Pharmaceuticals
- Eskayef Bangladesh Limited
- Esteve
- F. Hoffmann-La Roche Ltd., which owns Genentech and Chugai Pharmaceuticals
- Fabre-Kramer Pharmaceuticals
- Ferring Pharmaceuticals
- Fresenius Kabi
- Fresenius Medical Care
- Galderma Laboratories
- Gedeon Richter Ltd.
- General Pharma
- Gilead Sciences
- Glatt group
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- GPC Biotech
- Grifols
- Grindeks
- Gulf Pharmaceutical Industries (Julphar)
- G.F. Harvey Company
- Huadong Medicine
- Help Remedies
- Hetero Drugs
- Hexal Australia
- Hikma Pharmaceuticals
- Hoffmann-La Roche
- Horizon Pharma
- Hovione
- Incepta Pharmaceuticals
- Institute for OneWorld Health
- Intas Biopharmaceuticals
- Interphil Laboratories
- Ionis Pharmaceuticals
- Ipca Laboratories
- Ipsen
- Janssen Pharmaceutica
- Jenapharm
- JN-International Medical Corporation
- Johnson & Johnson
- Julphar
- Juno Therapeutics
- Kimia Farma
- Kyowa Hakko Kirin
- Lundbeck
- Lupin Limited
- Mallinckrodt Pharmaceuticals
- MannKind Corporation
- McGuff
- Medinfar
- Melior Discovery
- Menarini
- Merck & Co.
- Merck KGaA
- Mitsubishi Pharma
- Mylan
- Mayne Pharma
- NovaBay Pharmaceuticals
- Novartis
- Novo Nordisk
- Noxxon
- Octapharma
- Orexo
- OrgaNext
- Orion Pharma
- Ortho-McNeil Pharmaceutical
- Otsuka Pharmaceutical Co.
- Panacea Biotec
- Par Pharmaceutical
- Patheon
- Perrigo
- Pfizer
- Pharmaceutical Product Development
- Pharma Medica
- Pharma Nord
- Pharmacosmos
- Pharmascience
- Pierre Fabre Group
- Piramal Healthcare
- Pliva
- Procter & Gamble
- Purdue Pharma
- Ranbaxy Laboratories
- Reckitt Benckiser
- Regeneron Pharmaceuticals
- Renovo PLC
- Repligen
- Rubicon Research
- Salix Pharmaceuticals
- Sanofi
- Serum Institute of India
- Servier Laboratories
- Shionogi
- Shire plc
- SIGA Technologies
- Sigma Pharmaceuticals
- Sinopharm Group
- Solvay Group
- Square Pharmaceuticals
- STADA Arzneimittel
- Strides Arcolab
- Sun Pharmaceutical
- Sunovion
- Takeda Pharmaceutical Co.
- Tasly
- Teva Pharmaceuticals
- Taro Pharmaceuticals
- Torrent Pharmaceuticals
- Turing Pharmaceuticals
- UCB
- Unichem Laboratories
- USV Private Limited
- Valeant Pharmaceuticals International
- Veloxis Pharmaceuticals
- Vertex Pharmaceuticals
- Vion Pharmaceuticals, Inc.
- Wallace Pharmaceuticals
- Wockhardt
- Yuhan Corporation
- Zandu Pharmaceuticals
- Zentiva
For more information about this newsletter visit https://www.researchandmarkets.com/r/l7y38m
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900